https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

https://www.zh.ch/de/volkswirtschaftsdirektion/amt-fuer-wirtschaft/standortfoerderung.html  

8090 Zürich, Walchestrasse 19

 +41 43 259 49 92
 standort@vd.zh.ch

The Division of Business and Economic Development supports resident companies, promotes Zurich's innovation capacity by way of connecting the relevant stakeholders in key industries, fosters external economic relations and offers guidance to companies interested in moving to Zurich.

http://cdr-life.com/  

8810 Horgen, Tödistrasse 46

 info@cdr-life.com

CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://discopharma.de  

8952 Schlieren, Wagistrasse 25

Disco Pharmaceuticals is a young ETH spin-off company based in Zurich/Switzerland and Cologne/Germany. We leverage a novel mass spectrometric technology to investigate processes that are fundamental to cancer biology. We combine methodologies in cell biology, biochemistry, mass spectrometry with computational tools to identify proteins selectively expressed on cancer cells. Our ultimate goal is to develop innovative therapies for cancers with high unmet clinical need.

http://www.evitria.com/  

8951 Fahrweid, Brunaustrasse 185

 evitria@evitria.com

evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 50,000 transfections performed and more than 9,000 antibodies expressed and purified for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland) and affordable prices. Transfections are made with serum-free, animal-component free reagents at a monthly capacity of up to 500 liters. You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.

https://incephalo.com/  

8952 Schlieren, Wagistrasse 21

 office@incephalo.com

InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.

https://www.lifematrixtechnologies.com/  

8092 Zürich, c/o Wyss Zurich, Weinberstrasse 35

Based in Zurich, Switzerland, LifeMatrix Technologies AG, is a pre-revenue, high-tech startup company spun out of the Institute for Regenerative Medicine at the University of Zurich. Our team combines world leading science in cardiovascular tissue engineering with in-depth entrepreneurial expertise in medical biomimetic device development. The award winning LifeMatrix technology platform is backed by >20 years of research with >150 peer-reviewed publications and a strong patent portfolio. LifeMatrix is currently supported by the Wyss Zurich, a joint accelerator of the University of Zurich and ETH Zurich.